AzTrials
AzTrials

Low Anterior Resection SyndromeTraLARSNCT06222255

The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery (TraLARS)

A study testing Transanal Irrigation (TAI) in people with Low Anterior Resection Syndrome and Rectal Cancer, run by Seoul National University Hospital at 1 site in South Korea.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The preservation surgery of the anal sphincter muscle has become the standard procedure in the treatment of rectal cancer and, thanks to advancements in surgical techniques, can now be performed for tumors located closer to the anus. Read more about this study

Who is it for?
Ages 19 to 80 years
What is being tested?
Transanal Irrigation (TAI)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
52 participants
Where
1 siteSouth Korea
Study dates
6 Dec 2023to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 19 years and above.
  • Patients who have undergone low or ultra-low anterior resection surgery for rectal cancer (within 15cm from the anal verge).
  • Patients at least 24 months post-surgery (excluding those with incontinence, patients who have undergone postoperative cancer treatment should have completed treatment, and patients who have undergone bowel restoration surgery should be at least 6 months post-surgery, or for patients who received long-course preoperative radiotherapy, at least 18 months post-surgery).
  • Patients evaluated with a major LARS score who also have an ISI score of 3 or 4.
  • Patients who comprehend and have the ability to participate in this clinical trial.

Who cannot join

  • Patients currently taking medication for LARS within the last month.
  • Patients with a history of prior surgery for colorectal cancer.
  • Patients with recurrent colorectal cancer.
  • Patients with concomitant metastatic colorectal cancer.
  • Patients requiring permanent colostomy.
  • Patients who have undergone postoperative cancer radiation therapy.
Show all 13Show fewer
  • Patients with underlying conditions not controlled by internal medical treatment.
  • Patients with inflammatory bowel disease (IBD).
  • Patients with symptoms of constipation or diarrhea not controlled by medication.
  • Patients with preoperative symptoms of fecal incontinence.
  • Patients allergic to the investigational drug.
  • Patients deemed unsuitable for clinical trial participation by the principal investigator and study personnel.
  • Patients with ISI scores of 1 or 2.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Seung-Bum Ryoo, MD. PhD contact

+82-2-2072-4847

sbryoomd@gmail.com

South Korea1 site, 1 recruiting
  • Seoul National University Hospital

    Seoul, Jongro-gu, 03080

    Seung-Bum Ryoo, MD, PhD, +82-2-2072-7294, sbryoomd@gmail.com

    Recruiting

Other trials in South Korea

About this study

Official title: The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery: A Multicenter Prospective Randomized Controlled Trial (TraLARS)

The preservation surgery of the anal sphincter muscle has become the standard procedure in the treatment of rectal cancer and, thanks to advancements in surgical techniques, can now be performed for tumors located closer to the anus. This method allows patients to avoid a permanent artificial anus, maintaining continuity of the intestines and enabling bowel movements through the anus, making it a highly preferred procedure. Furthermore, advancements in various tumor treatments have led to improved long-term survival rates.

Preservation surgery of the anal sphincter muscle is commonly used in the treatment of rectal cancer, resulting in approximately 90% of patients experiencing changes in bowel habits after surgery. These changes include characteristic diarrhea, urgent bowel movements, frequent bowel movements, and fecal incontinence, collectively known as Anterior Resection Syndrome (ARS). Particularly in the case of low rectal cancer, it often manifests as Low Anterior Resection Syndrome (LARS). These symptoms are most severe immediately after surgery, generally persisting in a significant degree for 1-2 years, with some improvement over time. However, for many patients, LARS remains a lifelong challenge, significantly impacting their quality of life. Nighttime symptoms of LARS, in particular, have a profound effect on sleep quality, potentially leading to a decline in overall quality of life.

Read more

Currently, there is no definitive method to completely cure LARS, and the available approaches focus on empirical treatments or short-term symptom control using medications such as loperamide.

Loperamide directly affects the neuromuscular system of the intestine, reducing its motility. This prolongs the time food stays in the intestine, allowing sufficient absorption of moisture and electrolytes, consequently reducing symptoms of diarrhea. Loperamide is available in two forms: loperamide oxide and loperamide hydrochloride. While loperamide oxide products like Arestal® were prescribed by doctors until August 2017, the approval was revoked, leaving loperamide hydrochloride as the only form used domestically. It comes in a single product containing 2 mg of loperamide hydrochloride and a combination product with 0.25 mg of loperamide hydrochloride, a sterilizing agent in the intestine (e.g., acrylonitrile, berberine), and an antispasmodic.

Transanal irrigation (TAI) is a method where patients self-administer water into the rectum through an enema, physically cleansing the anus and rectum. This technique is often used for patients with chronic constipation or fecal incontinence. TAI has proven beneficial, particularly in improving symptoms for patients experiencing bowel dysfunction following sphincter-preserving surgery, especially for those who underwent low anterior resection.

However, there is currently no research on the utility and safety of TAI for LARS patients, specifically addressing whether it can improve the nighttime symptoms associated with LARS syndrome and enhance sleep quality. Therefore, this study aims to investigate the impact of TAI on the quality of sleep in patients with nighttime symptoms of LARS syndrome.

Being tested
Transanal Irrigation (TAI)
Medical subject headings
Low Anterior Resection Syndrome, Rectal Neoplasms, Sleep Initiation and Maintenance Disorders, Sleep Wake Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transanal Irrigation (TAI)Procedure or surgery

    The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).

Study groups in NCT06222255
Study groupRoleWhat they receive
Loperamide groupNo interventionThe group only takes loperamide in the evening.
Loperamide + Transanal irirgation groupExperimentalThe group takes Loperamide in the evening and undergoes Transanal irrigation before bedtime.
Receives: Procedure: Transanal Irrigation (TAI)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The LARS (Low Anterior Resection Syndrome) Score with Night symptoms

    A survey was conducted, scoring patients' symptoms related to LARS.

    Measured: 4 weaks

Secondary outcomes (3)
  1. Insomnia Severity Index score in Korean Validation

    A survey was conducted, scoring patients' symptoms related to Insomnia

    Measured: 4 weaks

  2. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - C30

    A survey was conducted, scoring patients' symptoms related to LARS and Quality of Life

    Measured: 4 weaks

  3. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - CR29

    A survey was conducted, scoring patients' symptoms related to LARS and Quality of Life

    Measured: 4 weaks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jan 2024
  2. Study start6 Dec 2023
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
52 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06222255
Sponsor's protocol ID
2310-121-1479
Acronym
TraLARS
Status last verified
Dec 2023
First submitted
8 Jan 2024
Last updated
24 Jan 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Transanal Irrigation (TAI) in people with Low Anterior Resection Syndrome and Rectal Cancer, run by Seoul National University Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Seung-Bum Ryoo, MD. PhD (+82-2-2072-4847, sbryoomd@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The LARS (Low Anterior Resection Syndrome) Score with Night symptoms (time frame: 4 weaks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in